Shares of Novo Nordisk ended higher on Monday and extended gains in after-hours trading, while "Big Pharma" rival Eli Lilly ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

The proposal would have enabled more Americans to afford new medications in the GLP-1 class that have been shown to reduce ...

Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

Last week, the Centers for Medicare & Medicaid Services said it will not go ahead with a plan from the Biden administration ...

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed ...

The Trump administration will not permit Medicare to pay for obesity drugs directly ... The decision is a setback for ...

The U.S. announced an increase in Medicare Advantage payment rates for 2026, exceeding expectations and affecting insurer ...

Extending coverage for the medications through Medicare could cost $35 billion over nine years, a congressional analysis ...